Stay updated on Interchangeability Study of ABP 654 in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FUnRfOfuFAjh1tnyz6dzLGHIN_Hc.uncropped.jpg&w=3840&q=75)
Latest updates to the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 88 locations and has been updated to revision v2.10.0, replacing the previous revision v2.9.7.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check24 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study details of a clinical trial investigating the interchangeability of ABP 654 for the treatment of participants with moderate to severe plaque psoriasis.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.0%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus related topics: Psoriasis Drug Information available for: Ustekinumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Double ( Participant Investigator ) Masking Description: The investigators, study personnel (with the exception of the Data Monitoring Committee (DMC), and unblinded Parexel staff supporting DMC activities and randomization list activities) and the study participants will remain blinded to treatment allocation.' This change reflects an update in the information displayed on the webpage.SummaryDifference58%
Stay in the know with updates to Interchangeability Study of ABP 654 in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page.